Laura Morrill

Laura Morrill is an Investment Director at Agathos Management LLP, a London-based, values-led lower-mid-market private equity firm founded in 2014 that backs UK service and tech-enabled businesses. She joined Agathos in 2023, focusing on sourcing and investing in growth-stage businesses and supporting their management teams post-investment. She has more than a decade of investing and advisory experience.

Before Agathos, Morrill spent six years at ECI Partners LLP, the UK growth-focused private equity firm, where she rose to Investment Director. There she partnered with growth-oriented services and software companies across healthcare, "tech for good," and business services, and led ECI's Healthcare and Life Sciences origination efforts. She began her career at PwC, where she spent five years in the Corporate Finance team advising privately owned and PE-backed businesses, and completed the CFA qualification during that time.

Morrill was a founding member of ECI's ESG Committee (established 2019) and has been an active advocate for ESG progress — particularly around diversity, equity and inclusion — a commitment she has carried into her ESG work at Agathos. She holds a first-class undergraduate degree in Land Economy and a Master's in Management, both from the University of Cambridge. Outside work she has been a competitive tennis player since childhood, with national and international experience.

• Invests in UK founder-led/founder-owned lower-mid-market companies (enterprise values up to ~£25m) via buyouts, management buyouts/buy-ins, founder de-risk deals, and growth equity — with primary cheques of roughly £5m–£10m.
• Screens deals against three core criteria in her own words: "growth, resilience and receptive management teams."
• Seeks "high growth businesses (with organic and inorganic stories) that demonstrate a sustainable, resilient earnings profile" — i.e., companies with both organic momentum and buy-and-build potential.
• Places heavy weight on the management team: "chemistry is therefore key" to a successful post-investment partnership, and she assesses management ambition plus "the quality of the data that they present," as a proxy for how well the business is run.
• Sector affinity for healthcare/life sciences and technology-enabled services; she has spoken about spending "a lot of time thinking about the impact of artificial intelligence on the healthcare industry and both the opportunities and risks."
• Strong ESG/DEI orientation, integrated into diligence and portfolio value-creation.